17 Aug Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Posted at 12:54h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACEls / Angiotensin receptor blockers (ARBs) and fluoroquinolones.
2019 Aug
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
16/08/2019
File Type:
pdf
Category:
Communication To Health Care Professionals